ANRO Stock Summary and Trading Ideas (Alto Neuroscience | NYSE:ANRO)

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.

As of November 12, 2026, ANRO stock price declined to $30.62 with 1,227,828 million shares trading.

ANRO has a beta of 0.49, meaning it tends to be less sensitive to market movements. ANRO has a correlation of 0.01 to the broad based SPY ETF.

ANRO has a market cap of $1.20 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ANRO has outperformed the market in the last year with a price return of +128.5% while the SPY ETF gained +12.0%. ANRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.4% and +31.2%, respectively, while the SPY returned -1.5% and -2.0%, respectively.

ANRO support price is $29.68 and resistance is $32.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.